Estrogen Receptor Positive Breast Cancer Treatment Market To Reach $33.7 Billion By 2030

Estrogen Receptor Positive Breast Cancer Treatment Market Growth & Trends

The global estrogen receptor positive breast cancer treatment market is anticipated to reach USD 33.7 billion by 2030 and is projected to grow at a CAGR of 7.89% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market includes a variety of therapeutic options specifically designed to target and manage this subtype of breast cancer. 

Innovations in drug development are significantly impacting the ER+ breast cancer treatment market. New therapies include novel aromatase inhibitors, selective estrogen receptor degraders (SERDs), and targeted treatments. For instance, in January 2023, the FDA authorized Orserdu, an oral prescription for metastatic estrogen receptor-positive, HER2-negative breast cancer with an ESR1 mutation, underscoring a shift towards personalized treatment strategies.

Strategic collaborations and partnerships between pharmaceutical companies, biotechnology firms, and research institutions significantly impact the market for ER+ breast cancer treatment. For instance, in June 2024, Menarini Group’s licensing agreement with Insilico Medicine to develop a new KAT6A inhibitor underscores the trend toward collaborative efforts to advance oncology treatments. These partnerships often lead to accelerated drug development and more comprehensive treatment options, enhancing the overall treatment landscape for ER+ breast cancer and contributing to market expansion.

 Request a free sample copy or view report summary: Estrogen Receptor Positive Breast Cancer Treatment Market Report

Estrogen Receptor Positive Breast Cancer Treatment Market Report Highlights

• Based on treatment, hormonal therapy dominated the market in 2023 due to its efficacy in improving patient outcomes, favorable side effect profiles compared with other modalities such as chemotherapy, long-term applicability as maintenance therapy, strong guideline support, patient preference trends towards less invasive options, economic considerations favoring cost-effective treatments, advancements in biomarker testing facilitating personalized medicine approaches, and continuous research leading to new therapeutic options within this category.

• Based on end use, hospitals dominated the market with the largest revenue share of 62.48% in 2023 due to their ability to provide comprehensive care through multidisciplinary teams, access to advanced treatments including clinical trials, demographic factors favoring older patients with complex needs, economic considerations regarding insurance coverage and cost efficiency, and their pivotal role in R&D efforts to improve patient outcomes.

Estrogen Receptor Positive Breast Cancer Treatment Market Segmentation

Grand View Research has segmented the global estrogen receptor positive breast cancer treatment market on the basis of treatment, end-use, and region:

Estrogen Receptor Positive Breast Cancer Treatment Outlook (Revenue, USD Million, 2018 - 2030)

• Chemotherapy

• Targeted Therapy

• Hormonal Therapy

• Radiation Therapy

• Other

Estrogen Receptor Positive Breast Cancer Treatment End-use Outlook (Revenue, USD Million, 2018 - 2030)

• Hospitals

• Specialty Clinics

• Other

Estrogen Receptor Positive Breast Cancer Treatment Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • Germany

  • UK

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • China

  • Japan

  • India

  • South Korea

  • Australia

  • Thailand

• Latin America

  • Brazil

  • Argentina

• Middle East and Africa (MEA)

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players in the Estrogen Receptor Positive Breast Cancer Treatment Market

• Radius Health, Inc.

• Sanofi

• F. Hoffmann-La Roche Ltd

• AstraZeneca

• Lilly

• EQRx, Inc.

• Gilead Sciences, Inc.

• Sermonix Pharmaceuticals

• Tyme Limited

• Genentech, Inc.